Supergen, Inc.
Records under this name other than patents Supergen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,710,057 | Imidazo[1,2-b]pyridazine and Pyrazolo[1,5-a]pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 7,750,007 | Imidazo[1,2-beta]pyridazine and PYRAZOLO[1,5-Alpha]PYRIMIDINE Derivatives and Their Use as Protein Kinase Inhibitors Formerly held In force · High confidence | In force | High confidence | |
| US 7,700,567 | Oligonucleotide Analogues Incorporating 5-AZA-CYTOSINE Therein Formerly held Term ended Term ended Sep 29, 2025 · High confidence | Term ended | Term ended Sep 29, 2025 | High confidence |
| US 8,461,123 | Oligonucleotide Analogues Incorporating 5-AZA-CYTOSINE Therein Formerly held Lapsed on the fee record Ended Jun 11, 2025 · High confidence | Lapsed on the fee record | Ended Jun 11, 2025 | High confidence |
| US 7,250,416 | Azacytosine Analogs and Derivatives Formerly held Term ended Term ended Mar 11, 2025 · High confidence | Term ended | Term ended Mar 11, 2025 | High confidence |
| US 6,710,195 | Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions Formerly held Term ended Term ended Nov 26, 2022 · From the USPTO record | Term ended | Term ended Nov 26, 2022 | From the USPTO record |
| US 7,135,464 | Method of Administering Decitabine Formerly held Term ended Term ended Jun 18, 2022 · Medium confidence | Term ended | Term ended Jun 18, 2022 | Medium confidence |
| US 7,144,873 | Kit for Delivering Decitabine in Vivo Formerly held Term ended Term ended Jun 18, 2022 · Medium confidence | Term ended | Term ended Jun 18, 2022 | Medium confidence |
| US 8,552,018 | Substituted Tricyclic Compounds as Protein Kinase Inhibitors Formerly held Lapsed on the fee record Ended Oct 8, 2021 · Medium confidence | Lapsed on the fee record | Ended Oct 8, 2021 | Medium confidence |
| US 8,445,502 | Pharmaceutical Formulations Comprising Salts of a Protein Kinase Inhibitor and Methods of Using Same Formerly held Lapsed on the fee record Ended May 21, 2021 · High confidence | Lapsed on the fee record | Ended May 21, 2021 | High confidence |